Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Research report - Business Express

United States Compounding Pharmacies Market is expected to reach a valuation around US$ 6.27 Billion by 2028 | FMI

USA Compounding Pharmacies Market by Product (Oral Medication, Topical Medication, Injectable, Mouthwashes, Nasal, Ocular, Others), Pharmacy (503A Pharmacy, 503B Pharmacy) & Region – Forecast 2022 – 2028

NEWARK, Del: The United States compounding pharmacies market is expected to exceed US$ 4.64 billion in 2020 and grow at a CAGR of more than 5.1% between 2022 and 2028. The growing emphasis on introducing novel formulations to combat various diseases is driving the market growth.

The U.S. compounding pharmacies market revenue is expected to increase at a robust growth rate over the next few years despite the reporting of several adverse events and drug mismanagement-related deaths. The U.S. compounding pharmacies market is expected to gain popularity in several regions of the U.S. due to upcoming products and therapeutic areas that are yet to be tapped by branded manufacturers.

Focus on factors, such as the availability of drugs in innovative medium/forms and the administration of varying dosages for various indications, is expected to drive the adoption of newer dosage forms of compounded medications. 

Sample of Research Report:

Market Remains Influenced by Availability of Compounded Pain Management Drugs

The growing popularity of pain management therapies is fuelling the growth of U.S. compounding pharmacies market. Compounded pain management drugs are not FDA-approved, however, they come under the State Pharmacies Board supervision in the U.S.

For example, medical guidelines such as the Chronic Pain Guidelines stated by the Medical Treatment Utilization Schedule (MTUS) do not support the use of compounds such as Gabapentin and Baclofen for pain management. However, compounding pharmacies use these compounds as well as several others in varying strengths to attract customers and increase their revenue.

Moreover, an increase in the shortage of prescription medicine is expected to upsurge the demand for compounding pharmacies. According to the U.S. FDA, only 154 drugs were in short supply or not available in 2007, as compared to 456 in 2012.

Currently, the number of drugs in short supply is around 300. Medicinal drought is prominent in the U.S. as compared to other countries, which is also fuelling the revenue growth of the U.S. compounding pharmacies market.  

On the other hand, increasing regulatory pressures are expected to hamper the growth of the U.S. compounding pharmacies market. Compounding pharmacies are engaged in trans-boundary drug compounding, and the manufacturing of bulk drugs & ingredients need to be registered with the FDA, undergo mandatory inspections, and abide by GMP guidelines.

Contact our Market Research Specialist:

For instance, the FDA has stated that around 70% of registered firms have been inspected, of which 28 firms have been issued FDA Form 483s (non-adherence to cGMP regulations and unsafe compounding practices), and five warning letters, which implies a very high rate of action.

Compounding pharmacies registering with the FDA could serve to increase credibility. However, inspections and compliance with good manufacturing practices is compulsory. Regulatory pressures on compounding pharmacies are expected to force the smaller ones to close their business primarily due to unsafe compounding practices, which are likely to directly impact patient safety.

Hormone Replacement Therapeutic Area to Hold over 38% Revenue Share in Market

By product type, oral medication is expected to dominate the U.S. compounding pharmacies market in terms of revenue, which is then followed by topical medication. The injectable segment by product type of the U.S. compounding pharmacies market is projected to grow at a significant rate as compared to other segments.

The hormone replacement therapy segment is the leading segment in terms of revenue among all the therapeutic area segments of the U.S. compounding pharmacies market, and is estimated to gain a 38.4% revenue share in 2022.

Among the pharmacy type segments, the 503A pharmacy segment is expected to gain a major revenue share as compared to the 503B pharmacy segment over the forecast period. By application, the adults segment is estimated to dominate the U.S. compounding pharmacies market, followed by the paediatrics segment. The veterinary segment is expected to grow at a faster pace as compared to the other application segments of the U.S. compounding pharmacies market.  

Buy This Report:

Key Companies Profiled:

  • Avella Specialty Pharmacy
  • Central Admixture Pharmacy Services Inc.
  • Hoye’s Pharmacy
  • Vertisis Custom Pharmacy
  • Smith Caldwell Drug Store
  • Sixth Avenue Medical Pharmacy
  • Cantrell Drug Company
  • Clinigen Group, Dougherty’s Pharmacy
  •  Fagron N.V.

U.S. Compounding Pharmacies Market By Category

By Product :

  • Oral Medication
    • Solid Medication
      • Capsules
      • Tablets
      • Mixtures
      • Lollipops
      • Lozenges
    • Liquid Medication
      • Syrup
      • Solution/li>
      • Emulsion
      • Suspension
    • Topical Medication
      • Gels
      • Ointments
      • Creams
      • Lotions
  • Injectable
  • Mouthwashes
  • Nasal
  • Ocular
  • Otic
  • Suppositories and Enemas

By Pharmacy Type :

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
  • 503A Pharmacy
  • 503B Pharmacy

By Application :

  • Adults
  • Pediatrics
  • Geriatrics
  • Veterinary

By Therapeutic Area :

  • Hormone Replacement Therapy
  • Pain Management
  • Dermatology
  • Oncology
  • Hematology
  • Dental
  • Others

Table of Content

  1. Executive Summary

      1.1. Market Outlook

      1.2. Analysis and Recommendations

  1. Market Overview

      2.1. Market Coverage / Taxonomy

      2.2. Market Definition

Complete TOC with Report Preview: 

Have a Look at Related Research Reports of Healthcare Domain:

Epidemic Keratoconjunctivitis Treatment Market Size – The global epidemic keratoconjunctivitis treatment market is expected to garner a market value of US$ 500 million in 2023 and is expected to accumulate a market value of US$ 814.45 million by registering a CAGR of 5% in the forecast period 2023 to 2033.

Softgel Capsules Market Share – The global softgel capsules market is expected to enjoy a valuation of US$ 1.1 Billion by the end of the year 2022, and further expand at a CAGR of 6.0% to reach a valuation of ~US$ 1.9 Billion by the year 2032.

Gastrointestinal Stent Market Growth – The global gastrointestinal stent market holds a valuation of US$ 455.44 Million by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 5.5%, and is expected to hold a market value of around US$ 815.34 Million in 2033.

Stoma/Ostomy Care Market Trends – The global stoma/ostomy care market holds a valuation of US$ 3.8 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 4.9%, and is expected to hold a market value of around US$ 6.5 Billion in 2033.

PD-L1 Biomarker Testing Market Demand – The global PD – L1 biomarker testing market holds a valuation of US$ 597.9 Million by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 9.14%, and is expected to hold a market value of around US$ 1.58 Billion in 2033.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

LinkedInTwitterBlogs | YouTube

For Sales Enquiries:

Recent Post: